Antibiotic developer Paratek Pharmaceuticals withdraws IPO

By Renaissance Capital,

Shutterstock photo

Paratek Pharmaceuticals, a biotech focused on the development of antibiotics, withdrew its plans for an initial public offering on Wednesday; the company did not cite reasons for its withdrawal. The Boston, MA-based company was founded in 1996 and submitted its initial filing in September of 2012. UBS Investment Bank and Leerink Swann were set to be the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: PRTK

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by